Coherus Oncology (CHRS) EBIT Margin Growth (1y) (2014 - 2026)

Coherus Oncology (CHRS) EBIT Margin Growth (1y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin Growth (1y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1,552.00
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1,536.00
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -170.00
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 1,276.00
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Coherus Oncology 194.37 Mn 27.32 Mn 8.50 Mn 30,424.00

Historic Data

Download Data
DateValue
Mar 31, 2026 30,424.00
Dec 31, 2025 22,699.00
Sep 30, 2025 39,108.00
Jun 30, 2025 -5,872.00
Mar 31, 2025 233,914.00
Dec 31, 2024 -51,160.00
Sep 30, 2024 -73,130.00
Jun 30, 2024 -32,604.00
Mar 31, 2024 -272,819.00
Dec 31, 2023 3,825.00
Sep 30, 2023 13,418.00
Jun 30, 2023 1,434.00
Mar 31, 2023 -7,424.00
Dec 31, 2022 -5,963.00
Sep 30, 2022 -13,736.00
Jun 30, 2022 -4,560.00
Mar 31, 2022 6,694.00
Dec 31, 2021 -6,879.00
Sep 30, 2021 -6,943.00
Jun 30, 2021 -7,571.00